{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:06:07Z","timestamp":1792807567423,"version":"4.5.0"},"reference-count":141,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The introduction of chimeric antigen receptor T (CAR-T) cell and bispecific antibody (BsAb) therapies has revolutionized multiple myeloma (MM) treatment, offering exceptional efficacy, and culminating in recent regulatory approval. However, these therapies have brought unique toxicity challenges, manifesting not only with the well-established cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), but also with the emergence of other common and equally distinctive toxicities, including cytopenias, hypogammaglobulinemia, infections, and the rare but life-threatening immune effector cell-like lymphohistiocytosis syndrome (IEC-HS). These adverse events are characterized by unique mechanisms of action that differ from those of previous treatments for MM, thereby requiring specialized knowledge to optimize day-to-day management and ultimately maximize therapeutic benefits while ensuring patient safety. Additionally, the toxicity profiles of these T-cell engager therapies are becoming increasingly important in treatment decisions, with implications for patient selection and therapy sequencing. In this review, we provide a comprehensive overview of the current state-of-the-art regarding the incidence, etiopathogenetic mechanisms, and clinical manifestations of these increasingly less non-prototypical but still lesser-known side effects than CRS and ICANS, in order to offer clear and actionable insights into their effective management, while emphasizing critical points for future improvement, in view of the increasing number of MM patients who will benefit from the newly approved and upcoming immunotherapies.<\/jats:p>","DOI":"10.3390\/cancers17091514","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:05:57Z","timestamp":1745989557000},"page":"1514","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1169-0129","authenticated-orcid":false,"given":"Katia","family":"Mancuso","sequence":"first","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Talarico","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Manzato","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7828-8230","authenticated-orcid":false,"given":"Simona","family":"Barbato","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9576-5118","authenticated-orcid":false,"given":"Paola","family":"Tacchetti","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-7305","authenticated-orcid":false,"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4514-3227","authenticated-orcid":false,"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Ailawadhi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"Dhakal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: A consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","article-title":"Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: A report from the International Myeloma Working Group Immunotherapy Committee","volume":"25","author":"Lin","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Usmani","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/jamaoncol.2024.2172","article-title":"B-Cell Maturation Antigen\/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma","volume":"10","author":"Qiang","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2023-182388","article-title":"Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"142","author":"Vij","year":"2023","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/14737140.2024.2344647","article-title":"Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma","volume":"24","author":"Tacchetti","year":"2024","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: Comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Tix","year":"2024","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Li, H., Zhao, L., Sun, Z., Yao, Y., Li, L., Wang, J., Hua, T., Ji, S., Wang, S., and Cheng, H. (2022). Prolonged hematological toxicity in patients receiving BCMA\/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1019548"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","article-title":"Comparison of infectious complications with BCMA-directed therapies in multiple myeloma","volume":"14","author":"Nath","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1182\/blood-2023-174477","article-title":"Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3","volume":"142","author":"Baz","year":"2023","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Sanoyan, D.A., Seipel, K., Bacher, U., Kronig, M.-N., Porret, N., Wiedemann, G., Daskalakis, M., and Pabst, T. (2023). Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed\/refractory multiple myeloma patients. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10824-3"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/bjh.19505","article-title":"French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed\/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry","volume":"205","author":"Ferment","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/bloodadvances.2024013540","article-title":"Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: A multicenter real-world experience","volume":"8","author":"Kalariya","year":"2024","journal-title":"Blood Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/14712598.2024.2433518","article-title":"Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma","volume":"1","author":"Mancuso","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti\u2013B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_27","unstructured":"Johnson & Johnson (2022, June 04). Longer-Term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI\u2122 (Ciltacabtagene Autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma. Available online: https:\/\/www.jnj.com\/media-center\/press-releases\/longer-term-data-from-cartitude-1-study-demonstrate-continued-deep-and-durable-responses-to-carvykti-ciltacabtagene-autoleucel-in-heavily-pretreated-patients-with-relapsed-or-refractory-multiple-myeloma."},{"key":"ref_28","unstructured":"Janssen Biotech, Inc. (2025, April 18). Carvykti-Ciltacabtagene Autoleucel. Available online: https:\/\/www.carvyktihcp.com\/carvykti-safety\/#AdverseReactions."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2023","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific","volume":"41","author":"Schinke","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8020","DOI":"10.1200\/JCO.2023.41.16_suppl.8020","article-title":"Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1","volume":"41","author":"Schinke","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1200\/JCO.2023.41.16_suppl.8012","article-title":"Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Hansen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2024","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): A first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2023-181857","article-title":"BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","article-title":"Anti\u2013G Protein\u2013Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase \u2161 Trial","volume":"41","author":"Xia","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2023-180421","article-title":"Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma","volume":"142","author":"Dima","year":"2023","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: A model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"ref_42","first-page":"2460","article-title":"How I Treat Cytopenias after CAR T-cell Therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: From mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1080\/10428194.2022.2056172","article-title":"Acute and delayed cytopenias following CAR T-cell therapy: An investigation of risk factors and mechanisms","volume":"63","author":"Brudno","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjh.19515","article-title":"Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed\/refractory multiple myeloma: Results from a prospective comprehensive biomarker study","volume":"205","author":"Zhou","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1182\/bloodadvances.2023012522","article-title":"Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma","volume":"8","author":"Berastegui","year":"2024","journal-title":"Blood Adv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1097\/HS9.0000000000000957","article-title":"Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients","volume":"7","author":"Panagiota","year":"2023","journal-title":"HemaSphere"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2023-182522","article-title":"CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias","volume":"142","author":"Hamilton","year":"2023","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S2152-2650(24)01847-0","article-title":"OA-06 Impact of Clonal Hematopoiesis on Clinical Outcomes to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma","volume":"24","author":"Gustine","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv."},{"key":"ref_51","first-page":"541","article-title":"Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: Pooled analysis of data from phase 3 and 4 clinical trials","volume":"56","author":"Moots","year":"2017","journal-title":"Rheumatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jcyt.2022.11.001","article-title":"Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor\u2013T-cell therapy","volume":"25","author":"Wang","year":"2023","journal-title":"Cytotherapy"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41375-023-02129-y","article-title":"Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed\/refractory myeloma","volume":"38","author":"Fischer","year":"2024","journal-title":"Leukemia"},{"key":"ref_54","first-page":"e44677","article-title":"Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series","volume":"15","author":"Dhaliwal","year":"2023","journal-title":"Cureus"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transpl. Cell Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5414\/CNCS111045","article-title":"Thrombotic microangiopathy following chimeric antigen receptor T-cell therapy","volume":"11","author":"Wu","year":"2023","journal-title":"Clin. Nephrol.\u2013Case Stud."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.2021014611","article-title":"T-cell\u2013redirecting bispecific antibodies in multiple myeloma: A revolution?","volume":"139","author":"Moreau","year":"2022","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Tacchetti, P., Barbato, S., Mancuso, K., Zamagni, E., and Cavo, M. (2024). Bispecific Antibodies for the Management of Relapsed\/Refractory Multiple Myeloma. Cancers, 16.","DOI":"10.3390\/cancers16132337"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2023-191305","article-title":"Pooled Analysis on Bispecific Antibody-Related Toxicities in Multiple Myeloma","volume":"142","author":"Golmohammadi","year":"2023","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/s41409-020-01006-x","article-title":"G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory\/relapsed B-cell lymphoma","volume":"55","author":"Galli","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"E399","DOI":"10.1002\/ajh.26313","article-title":"The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy","volume":"96","author":"Barreto","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41409-021-01526-0","article-title":"Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma","volume":"57","author":"Morin","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-022-00741-2","article-title":"Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma","volume":"12","author":"Miller","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jcyt.2023.01.011","article-title":"Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma","volume":"25","author":"Ma","year":"2023","journal-title":"Cytotherapy"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.1182\/blood-2022-167976","article-title":"G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell Therapy","volume":"140","author":"Bindal","year":"2022","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/s41409-019-0674-2","article-title":"Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA\u2013CAR-T therapy in patient with relapsed myeloma","volume":"55","author":"Lin","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1182\/bloodadvances.2022007572","article-title":"CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy","volume":"6","author":"Mullanfiroze","year":"2022","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1182\/bloodadvances.2022007776","article-title":"Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy","volume":"6","author":"Rejeski","year":"2023","journal-title":"Blood Adv."},{"key":"ref_73","first-page":"567","article-title":"Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy","volume":"29","author":"Davis","year":"2023","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/bloodadvances.2022008042","article-title":"Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: A GLA\/DRST study","volume":"7","author":"Gagelmann","year":"2023","journal-title":"Blood Adv."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41409-024-02233-2","article-title":"Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma","volume":"59","author":"Mohan","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e002721","DOI":"10.1136\/jitc-2021-002721","article-title":"Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: A case report","volume":"9","author":"Baur","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00277-022-04889-6","article-title":"Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells\u2014Single-center experience","volume":"101","author":"Perry","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/bloodadvances.2022008066","article-title":"Prolonged thrombocytopenia after CAR T-cell therapy: The role of thrombopoietin receptor agonists","volume":"7","author":"Drillet","year":"2023","journal-title":"Blood Adv."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/ejh.14141","article-title":"Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias","volume":"112","author":"Wesson","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/ACI.0000000000000215","article-title":"Secondary antibody deficiencies","volume":"15","author":"Dhalla","year":"2015","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.15433","article-title":"Infectious and immunological sequelae of daratumumab in multiple myeloma","volume":"185","author":"Johnsrud","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"AB231","DOI":"10.1016\/j.jaci.2023.11.741","article-title":"Hypogammaglobulinemia and Risk of Infection Following Daratumumab in Patients with Multiple Myeloma","volume":"153","author":"Hong","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"100810","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2249.2008.03851.x","article-title":"Clinical Immunology Review Series: An approach to the management of pulmonary disease in primary antibody deficiency","volume":"155","author":"Tarzi","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jmv.1890360113","article-title":"Immunoglobulin G subclasses and lymphocyte stimulatory responses to cytomegalovirus in transplant patients with primary cytomegalovirus infections","volume":"36","author":"Mathiesen","year":"1992","journal-title":"J. Med. Virol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1182\/bloodadvances.2023010524","article-title":"Respiratory infections predominate after day 100 following B-cell maturation antigen\u2013directed CAR T-cell therapy","volume":"7","author":"Little","year":"2023","journal-title":"Blood Adv."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e2238961","DOI":"10.1001\/jamanetworkopen.2022.38961","article-title":"Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma","volume":"5","author":"Hammons","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"AB224","DOI":"10.1016\/j.jaci.2022.12.698","article-title":"Hypogammaglobulinemia and Risk of Infectious Complications in Patients Receiving Idecabtagene vicleucel","volume":"151","author":"Barmettler","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: Consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: Importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e14157","DOI":"10.1111\/tid.14157","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref_99","first-page":"304.e1","article-title":"Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma","volume":"28","author":"Josyula","year":"2022","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/bloodadvances.2024013461","article-title":"Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma","volume":"8","author":"Ludwig","year":"2024","journal-title":"Blood Adv."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2024-199542","article-title":"Cevostamab in Patients with Heavily Pretreated Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies","volume":"144","author":"Richter","year":"2024","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: A national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: A pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: A systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Zhu, F., Wei, G., Liu, Y., Zhou, H., Wu, W., Yang, L., Huang, H., and Hu, Y. (2021). Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed\/Refractory B-cell Malignancies. Cell Transplant., 30.","DOI":"10.1177\/09636897211025503"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-022-00716-3","article-title":"\u03b3-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation","volume":"12","author":"Chen","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/blood-2023-173550","article-title":"Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1\/2 MajesTEC-1 Study of Patients with Relapsed\/Refractory Multiple Myeloma","volume":"142","author":"Vishwamitra","year":"2023","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-Cell Characteristics Impact Response and Resistance to T-Cell\u2013Redirecting Bispecific Antibodies in Multiple Myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1097\/HS9.0000000000000858","article-title":"Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed\/Refractory B-NHL","volume":"7","author":"Rejeski","year":"2023","journal-title":"Hemasphere"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41408-021-00563-8","article-title":"Viral infection\/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/CJI.0000000000000388","article-title":"CMV and HSV Pneumonia After Immunosuppressive Agents for Treatment of Cytokine Release Syndrome Due to Chimeric Antigen Receptor\u2013modified T (CAR-T)-Cell Immunotherapy","volume":"44","author":"Heldman","year":"2021","journal-title":"J. Immunother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1002\/jmv.27257","article-title":"Severe cytomegalovirus disease with encephalitis after CAR-T cell therapy: A rare but potentially fatal complication","volume":"93","author":"Cousin","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s40425-019-0790-y","article-title":"Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma","volume":"7","author":"Wei","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood.2020004907","article-title":"Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy","volume":"136","author":"Cao","year":"2020","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","article-title":"Infectious complications of bispecific antibody therapy in patients with multiple myeloma","volume":"13","author":"Sim","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"Gleason","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: A consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Mancuso, K., Zamagni, E., Solli, V., Gabrielli, L., Leone, M., Pantani, L., Rocchi, S., Rizzello, I., Tacchetti, P., and Ghibellini, S. (2023). Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1208741"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/infdis\/jis212","article-title":"Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B Cells","volume":"205","author":"Clutterbuck","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e14109","DOI":"10.1111\/tid.14109","article-title":"Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy","volume":"25","author":"Reynolds","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e1309654","DOI":"10.1097\/01.HS9.0000967696.13096.54","article-title":"Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed\/Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study","volume":"7","author":"Mohty","year":"2023","journal-title":"Hemasphere"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e90600b0","DOI":"10.1097\/01.HS9.0000970428.90600.b0","article-title":"P881: Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study","volume":"7","author":"Bhutani","year":"2023","journal-title":"HemaSphere"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-024-01119-2","article-title":"Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: Clinical presentation, outcomes, and management","volume":"14","author":"Khurana","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_132","unstructured":"(2025, April 18). ABECMA (Idecabtagene Vicleucel) Package Insert, Available online: https:\/\/www.fda.gov\/media\/147055\/download."},{"key":"ref_133","unstructured":"(2025, April 18). CARVYKTI (Ciltacabtagene Autoleucel) Package Insert, Available online: https:\/\/www.fda.gov\/media\/156560\/download."},{"key":"ref_134","unstructured":"(2024, March 21). Bristol Myers Squibb\u2019s Abecma (Idecabtagene Vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma. Available online: https:\/\/news.bms.com\/news\/corporate-financial\/2024\/Bristol-Myers-Squibbs-Abecma-idecabtagene-vicleucel-Becomes-First-CAR-T-Cell-Therapy-Approved-in-the-European-Union-in-Earlier-Lines-for-Triple-Class-Exposed-Relapsed-and-Refractory-Multiple-Myeloma\/default.aspx."},{"key":"ref_135","unstructured":"J&J (2024, April 01). CARVYKTI\u00ae Is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy. Available online: https:\/\/www.jnj.com\/media-center\/press-releases\/carvykti-is-the-first-and-only-bcma-targeted-treatment-approved-by-the-u-s-fda-for-patients-with-relapsed-or-refractory-multiple-myeloma-who-have-received-at-least-one-prior-line-of-therapy."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"439572","DOI":"10.1200\/JCO.2024.42.36_suppl.439572","article-title":"Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"Mateos","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s43018-024-00821-1","article-title":"ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells","volume":"5","author":"Hall","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1182\/blood-2024-198499","article-title":"Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and\/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial","volume":"144","author":"Freeman","year":"2024","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1514\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:24:42Z","timestamp":1760030682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":141,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["cancers17091514"],"URL":"https:\/\/doi.org\/10.3390\/cancers17091514","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]}}}